VIPoma MRI: Difference between revisions
Jump to navigation
Jump to search
Madhu Sigdel (talk | contribs) No edit summary |
m (Bot: Removing from Primary care) |
||
| (6 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{VIPoma}} | {{VIPoma}} | ||
{{CMG}}{{AE}}{{MSI}}{{PSD}} | {{CMG}}{{AE}}{{MSI}}{{PSD}}{{Homa}} | ||
==Overview== | ==Overview== | ||
Abdominal MRI is helpful in the diagnosis of VIPoma. On abdominal MRI, VIPoma is characterized by a mass which is hypointense on T1-weighted MRI and hyperintense on T2-weighted MRI. | [[Abdominal]] [[MRI]] is helpful in the [[diagnosis]] of VIPoma. On [[abdominal]] [[MRI]], VIPoma is characterized by a [[mass]] which is hypointense on [[T1]]-weighted [[MRI]] and hyperintense on T2-weighted [[MRI]]. | ||
==MRI== | ==MRI== | ||
*Findings on abdominal MRI suggestive of VIPoma include: | *Findings on [[abdominal]] [[Magnetic resonance imaging|MRI]] suggestive of VIPoma include:<ref name="SofkaSemelka1997">{{cite journal|last1=Sofka|first1=Carolyn M.|last2=Semelka|first2=Richard C.|last3=Marcos|first3=Hani B.|last4=Woosley|first4=John T.|title=MR Imaging of metastatic pancreatic VIPoma|journal=Magnetic Resonance Imaging|volume=15|issue=10|year=1997|pages=1205–1208|issn=0730725X|doi=10.1016/S0730-725X(97)00201-4}}</ref><ref name="Reidy-LagunesGollub2011">{{cite journal|last1=Reidy-Lagunes|first1=Diane L.|last2=Gollub|first2=Marc J.|last3=Saltz|first3=Leonard B.|title=Addition of Octreotide Functional Imaging to Cross-Sectional Computed Tomography or Magnetic Resonance Imaging for the Detection of Neuroendocrine Tumors: Added Value or an Anachronism?|journal=Journal of Clinical Oncology|volume=29|issue=3|year=2011|pages=e74–e75|issn=0732-183X|doi=10.1200/JCO.2010.32.8559}}</ref> | ||
**[[T1]]-weighted [[MRI]]: hypointense signal | |||
**T2-weighted [[MRI]]: hyperintense signal | |||
== | *[[MRI]] with [[gadolinium]] enhancement is more sensitive compared to [[CT scan]] in [[diagnosis]] of [[liver]] [[metastases]] which are shown as peripheral ring enhancement. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Medicine]] | |||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category: | [[Category:Up-To-Date]] | ||
[[Category:Endocrinology]] | |||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category: | [[Category:Radiology]] | ||
Latest revision as of 00:40, 30 July 2020
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma MRI On the Web |
|
American Roentgen Ray Society Images of VIPoma MRI |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]
Overview
Abdominal MRI is helpful in the diagnosis of VIPoma. On abdominal MRI, VIPoma is characterized by a mass which is hypointense on T1-weighted MRI and hyperintense on T2-weighted MRI.
MRI
- Findings on abdominal MRI suggestive of VIPoma include:[1][2]
- MRI with gadolinium enhancement is more sensitive compared to CT scan in diagnosis of liver metastases which are shown as peripheral ring enhancement.
References
- ↑ Sofka, Carolyn M.; Semelka, Richard C.; Marcos, Hani B.; Woosley, John T. (1997). "MR Imaging of metastatic pancreatic VIPoma". Magnetic Resonance Imaging. 15 (10): 1205–1208. doi:10.1016/S0730-725X(97)00201-4. ISSN 0730-725X.
- ↑ Reidy-Lagunes, Diane L.; Gollub, Marc J.; Saltz, Leonard B. (2011). "Addition of Octreotide Functional Imaging to Cross-Sectional Computed Tomography or Magnetic Resonance Imaging for the Detection of Neuroendocrine Tumors: Added Value or an Anachronism?". Journal of Clinical Oncology. 29 (3): e74–e75. doi:10.1200/JCO.2010.32.8559. ISSN 0732-183X.